Navigation Links
Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
Date:6/19/2013

ites internationally, and 86 percent of patients had intermediate or high-risk MCL. Study participants received a 560mg daily oral dose of ibrutinib monotherapy and were treated into two cohorts based on prior exposure to bortezomib – either no prior bortezomib (n=63) or prior bortezomib (n=48). Overall, patients had received a median of three prior therapies.

About Mantle Cell Lymphoma
MCL, a B-cell malignancy, is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) that usually occurs in older adults. The disease typically begins in the lymph nodes but can spread to other tissues, such as bone marrow and liver. Ibrutinib targets the B-cell receptor pathway an important pathway in malignant B-cell growth and proliferation. In the United States there are approximately 5,000 new cases of MCL each year.

About Ibrutinib
Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel —regulation of apoptosis, cell adhesion, and cell migration and homing.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date six Phase 3 trials have been initiated with ibrutinib and a total of 30 trials are currently registered on www.clinicaltrials.gov. Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commerciali
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
2. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
3. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
4. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
5. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
8. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
10. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
11. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... NEW YORK , Dec. 22, 2014 /PRNewswire/ ... developing novel therapies for the treatment of chronic ... subjects has been dosed in a pharmacokinetic and ... receptor antagonist for neuropathic pain. Racemic ... treatment of various pain states and substitution therapy ...
(Date:12/19/2014)... 2014 TODAY, AEGATE, the leader ... announced the appointment of Peter Fox as ... Channels and Partner Officer. Peter has served ... its acquisition by Oracle in 2011. Prior ... Geneva and subsequently Convergys, a world renowned ...
(Date:12/19/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB:  ... in the development of brachytherapy devices and medical ... that a Life Sciences Discovery Fund (LSDF) Proof ... AMIC is the commercialization partner.  The award was ... proposal titled "Optimized Injectable Radiogels for High-dose Therapy ...
Breaking Medicine Technology:Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... Schering-Plough Corporation,(NYSE: SGP ) today reported that ... Phase II study of boceprevir, its investigational oral ... chronic,hepatitis C virus (HCV) genotype 1 were presented ... for the Study of the Liver (EASL). The,ongoing ...
... Into New Promising Drugs to Combat Hepatitis ... C ... Stem Cells of Potential Benefit in Liver Transplantation, ... At today,s sessions of the 43rd Annual Meeting of the European,Association for the ...
Cached Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
(Date:12/22/2014)... 2014 Super Saturday, the last Saturday ... as the busiest day in the 2014 holiday shopping ... Station had a steady pre-Christmas stream of customers, ready ... Saturday. , “I definitely intend to take advantage…of the ... resident who was enjoying The Grass Station’s holiday sale ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Give a ... season, the gift of health and vitality. , For ... its three top-selling anti-aging formulas in special Holiday Wellness ... rush delivery. , Each bottle contains cutting-edge, proven ... that don't work as well as we age. ...
(Date:12/22/2014)... December 22, 2014 Pasadena sleep ... consultations for sleep apnea. Drowsy drivers are 15 times ... who are well-rested, and some experts believe that sleep-deprived ... as intoxicated drivers. Unfortunately, millions of Americans may be ... Academy of Sleep Medicine, about 18 million Americans have ...
(Date:12/22/2014)... TheHardwareCity.com now stocks MagnoGrip Pro Utility Magnetic ... Customers of the large online tool shop enjoy a ... to their home or workplace with free shipping. , ... heavy duty magnets, which make work easier. The patented ... metal parts on the back of their hand, including ...
(Date:12/22/2014)... NAPW honors Michelle M. ... Year. Ms. Foley is recognized with this prestigious distinction ... organization of professional women in the country, spanning virtually ... Women is a powerfully vibrant networking community with over ... a nurse, I felt like I made a difference ...
Breaking Medicine News(10 mins):Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2
... Jan. 27 Hooper Holmes (Amex: HH ... as Senior Vice President, General Counsel and Corporate Secretary. ... of Hooper Holmes, Inc.Mr. Rosenblum has over 23 years ... including intellectual property, securities, contract, consumer and other class ...
... Net Product Sales Increased 9% Over 2007 to $765.3 ... 2010SAN DIEGO, Calif., Jan. 27 Amylin Pharmaceuticals, Inc. ... for the quarter and year ended December 31, 2008. ... the quarter ended December 31, 2008, which includes net ...
... Systems, Inc. (NASDAQ: MRCY ), a leading ... complex image, sensor, and signal processing applications, announced that ... sale of its wholly-owned subsidiaries, Visage Imaging(R), Inc. and ... Limited. The financial terms of the transaction were not ...
... to Public OpinionWASHINGTON, Jan. 27 Political considerations ... from President Obama,s huge economic stimulus package, despite ... their high level of public approval.A recent Lake ... Women Donors Network in early November 2008 around ...
... could help treat depression, other disorders, researchers say , , ... scientists say they,ve devised a potential new method ... the natural dynamics of the body,s "fight or flight" ... adrenal (HPA) axis, one of the body,s major control ...
... just watching symptoms leads to similar survival rates in ... Using the biomarker molecule known as brain natriuretic peptide ... heart failure did not improve the clinical outcome in ... been conflicting reports about the value of monitoring blood ...
Cached Medicine News:Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 2Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 3Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 2Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 3Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 4Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 5Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 6Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 7Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 8Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 9Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 10Health News:Mercury Computer Systems Announces the Sale of Visage Imaging to Pro Medicus Limited 2Health News:Mercury Computer Systems Announces the Sale of Visage Imaging to Pro Medicus Limited 3Health News:Mercury Computer Systems Announces the Sale of Visage Imaging to Pro Medicus Limited 4Health News:Family Planning Again Becomes Political Football 2Health News:Family Planning Again Becomes Political Football 3Health News:Monitoring Protein Didn't Improve Heart Failure Outcomes 2Health News:Monitoring Protein Didn't Improve Heart Failure Outcomes 3
The Storz Protege is an anterior segment unit only....
The CV-12000 provides the surgeon with all the options to perform today's newest techniques....
Phaco-emulsification systems CV series...
The unprecedented power, flexibility and versatility of the Series 20000 Legacy have made it the world's leading phacoemulsifier....
Medicine Products: